China's Best One-Stop Medical Equipment Provider
About

The IvyGene test is a ground-breaking new blood test that uses advanced DNA Sequencing methods to detect the DNA methylation pattern of ctDNA in plasma samples in order to both confirm the presence of methylation patterns consistent with disease presence and give quantifiable data about disease presence. Please, visit our website! www.ivygenelabs.com Testing services are available now! DNA within cells can be modified by the addition of a methyl group (-CH3) to select sites within the genome. Depending on where the site is located within the genome, these DNA methylation sites can be indicators that a particular gene is being expressed (activated) or silenced (inactivated). Consequentially, normal cells and cancer cells can be differentiated by detecting which of these sites within the genome are methylated. During malignant transformation (the process by which normal cells transform into cancer cells), there are significant changes in gene expression. These changes in gene expression are highly correlated to changes to the methylation pattern of genomic DNA. The genomic DNA of cancer cells can be shed into circulation due to cancer cell death (apoptosis or necrosis) or release from viable cells. Once the genomic DNA of a cancer cell is shed into the blood stream, it is called circulating tumor DNA (ctDNA). This ctDNA retains the DNA methylation pattern of the cancer cell form which is was shed. IvyGene is intended to be used in conjunction with other diagnostic tests, not to replace normal standards of care.

Technologies
Cloudflare DNS CloudFlare Hosting YouTube Mobile Friendly Facebook Widget reCAPTCHA Woo Commerce Google Font API WordPress.org Facebook Custom Audiences Facebook Login (Connect) Google Tag Manager Gravity Forms AddThis Google Maps AI
Keywords
genetic sequencing cancer research noninvasive multiple tissues of origin dna methylation blood test medical equipment manufacturing biomarker validation cell-free dna next-generation sequencing biotechnology cancer systemic burden assessment early detection b2c clinical validation services dna methylation markers ai technology d2c diagnostic platform fda breakthrough device cell-free dna analysis clinical trial ai sequencing cancer tissue mapping cancer detection proactive cancer screening medical and diagnostic laboratories multi-cancer detection methylation patterns
Company Information
  • Employees 1
  • Founded 2017
Location

1201 Cumberland Ave, West Lafayette, Indiana, United States, 47906-1317

Related Companies
Companies in the same industry